

# The Cost Effectiveness of Implantable Cardioverter-Def

Journal of the American College of Cardiology  
47, 2310-2318

DOI: 10.1016/j.jacc.2006.03.032

Citation Report

#	ARTICLE	IF	CITATIONS
1	Cost Effectiveness of the Implantable Cardioverter-Defibrillator: Better in Higher-Risk Patients and Extended Duration. Preventive Cardiology, 2006, 9, 131-132.	1.1	3
2	Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Death in Heart Failure. Circulation, 2006, 114, 101-103.	1.6	152
3	The high cost of implantable defibrillators. European Heart Journal, 2007, 28, 388-391.	2.2	44
4	The cost of implantable defibrillators: how the perception of reality depends on perspective. European Heart Journal, 2007, 28, 386-387.	2.2	9
5	Sudden Death Prevention With Implantable Devices. Circulation, 2007, 116, 561-571.	1.6	45
6	Current News in Cardiology. , 2007, , .		0
7	Systematic Review: Implantable Cardioverter Defibrillators for Adults with Left Ventricular Systolic Dysfunction. Annals of Internal Medicine, 2007, 147, 251.	3.9	146
8	The nature of heart failure as a challenge to the integration of palliative care services. Current Opinion in Supportive and Palliative Care, 2007, 1, 249-254.	1.3	22
9	Health-Related Quality of Life Consequences of Implantable Cardioverter Defibrillators. Medical Care, 2007, 45, 377-385.	2.4	57
10	A 59-Year-Old Man Considering Implantation of a Cardiac Defibrillator. JAMA - Journal of the American Medical Association, 2007, 297, 1909.	7.4	7
11	Effect of oral $\beta$ -blocker therapy on microvolt T-wave alternans and electrophysiology testing in patients with ischemic cardiomyopathy. American Heart Journal, 2007, 153, 392-397.	2.7	21
13	Palliative Care and Hospice in Advanced Heart Failure. Journal of Palliative Medicine, 2007, 10, 210-228.	1.1	68
14	Effect of bundle branch block on microvolt T-wave alternans and electrophysiologic testing in patients with ischemic cardiomyopathy. Heart Rhythm, 2007, 4, 904-912.	0.7	27
15	Where are we, and where are we heading in the device management of ventricular tachycardia/ventricular fibrillation?. Heart Rhythm, 2007, 4, 99-103.	0.7	4
16	The Year in Epidemiology, Health Services Research, and Outcomes Research. Journal of the American College of Cardiology, 2007, 50, 2254-2262.	2.8	1
18	On the equivalence of some medical cost estimators with censored data. Statistics in Medicine, 2007, 26, 4520-4530.	1.6	40
19	Sudden cardiac death: Epidemiologic and financial worldwide perspective. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 199-203.	1.3	46
20	Socio-economic analysis of cardiac resynchronization therapy. Journal of Interventional Cardiac Electrophysiology, 2007, 17, 225-236.	1.3	3

#	ARTICLE	IF	CITATIONS
21	Prevalence and mortality of patients with myocardial infarction and reduced left ventricular ejection fraction in a defined community: Relation to the second multicenter automatic defibrillator implantation trial. Journal of Interventional Cardiac Electrophysiology, 2007, 19, 157-164.	1.3	9
22	Treatment of asymptomatic left ventricular dysfunction. Current Treatment Options in Cardiovascular Medicine, 2008, 10, 476-485.	0.9	2
23	A Study on Confidence Intervals for Incremental Cost-Effectiveness Ratios. Biometrical Journal, 2008, 50, 505-514.	1.0	27
24	Risk stratification of patients with prior myocardial infarction and advanced left ventricular dysfunction by gated myocardial perfusion SPECT imaging. Journal of Nuclear Cardiology, 2008, 15, 631-637.	2.1	27
25	Sudden cardiac death: influence of diabetes. Diabetes, Obesity and Metabolism, 2008, 10, 523-532.	4.4	18
26	Long QT Syndrome. Current Problems in Cardiology, 2008, 33, 629-694.	2.4	174
27	Evaluación económica de los desfibriladores automáticos implantables. Revista Espanola De Cardiología Suplementos, 2008, 8, 9A-21A.	0.2	0
28	Implantable Device Therapy. Progress in Cardiovascular Diseases, 2008, 50, 449-474.	3.1	21
29	Noninvasive Risk Stratification for Sudden Death: Signal-Averaged Electrocardiography, Nonsustained Ventricular Tachycardia, Heart Rate Variability, Baroreflex Sensitivity, and QRS Duration. Progress in Cardiovascular Diseases, 2008, 51, 106-117.	3.1	31
30	Risk Stratification for Primary Implantation of a Cardioverter-Defibrillator in Patients With Ischemic Left Ventricular Dysfunction. Journal of the American College of Cardiology, 2008, 51, 288-296.	2.8	492
31	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Journal of the American College of Cardiology, 2008, 51, e1-e62.	2.8	1,798
32	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary. Journal of the American College of Cardiology, 2008, 51, 2085-2105.	2.8	184
33	Long QT Syndrome. Journal of the American College of Cardiology, 2008, 51, 2291-2300.	2.8	458
34	A Critical Appraisal of Implantable Cardioverter-Defibrillator Therapy for the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2008, 52, 1111-1121.	2.8	318
35	Benefits of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2008, 52, 1122-1127.	2.8	39
36	Does Microvolt T-Wave Alternans Testing Predict Ventricular Tachyarrhythmias in Patients With Ischemic Cardiomyopathy and Prophylactic Defibrillators?. Journal of the American College of Cardiology, 2008, 52, 1607-1615.	2.8	180
37	Interpreting the Results of Cost-Effectiveness Studies. Journal of the American College of Cardiology, 2008, 52, 2119-2126.	2.8	209
38	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Heart Rhythm, 2008, 5, e1-e62.	0.7	283

#	ARTICLE	IF	CITATIONS
39	Preventing tomorrow's sudden cardiac death today. American Heart Journal, 2008, 156, 613-622.	2.7	46
40	What is the real world for analyzing outcomes and costs of ICD therapy?. Heart Rhythm, 2008, 5, 654-655.	0.7	1
41	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary. Heart Rhythm, 2008, 5, 934-955.	0.7	367
43	Use of Traditional and Biventricular Implantable Cardiac Devices for Primary and Secondary Prevention of Sudden Death. Cardiology Clinics, 2008, 26, 419-431.	2.2	5
44	Primary prevention of sudden cardiac death using implantable cardioverter defibrillators. Europace, 2008, 10, 1034-1041.	1.7	6
45	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities: Executive Summary. Circulation, 2008, 117, 2820-2840.	1.6	175
46	ACC/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2008, 117, e350-408.	1.6	1,358
47	Impact of advanced age on survival in patients with implantable cardioverter defibrillators. Europace, 2008, 10, 1296-1301.	1.7	46
48	Cost Sharing for Health Care – Whose Skin? Which Game?. New England Journal of Medicine, 2008, 358, 411-413.	27.0	9
49	Trends in Cardiovascular Devices. Journal of Clinical Engineering, 2008, 33, 209-243.	0.1	0
50	The economical challenge in the treatment of chronic heart failure: is primary prophylactic ICD therapy cost-effective in Europe?. Europace, 2009, 11, 689-691.	1.7	5
51	Editorial: The economical challenge in the treatment of chronic heart failure: is primary prophylactic implantable cardioverter defibrillator therapy cost-effective in Europe?. Europace, 2009, 11, 1407-1408.	1.7	0
52	Predicting future shocks in implantable cardioverter defibrillator recipients: the role of biomarkers. Europace, 2009, 11, 1434-1439.	1.7	1
53	The economical challenge in the treatment of chronic heart failure: is primary prophylactic ICD therapy cost-effective in Europe? Reply. Europace, 2009, 11, 1408-1410.	1.7	0
54	Expenditure and value for money: the challenge of implantable cardioverter defibrillators. QJM - Monthly Journal of the Association of Physicians, 2009, 102, 349-356.	0.5	22
55	Lifetime cost-effectiveness of prophylactic implantation of a cardioverter defibrillator in patients with reduced left ventricular systolic function: results of Markov modelling in a European population. Europace, 2009, 11, 716-726.	1.7	74
56	Effectiveness of Implantable Cardioverter-Defibrillators for the Primary Prevention of Sudden Cardiac Death in Women With Advanced Heart Failure. Archives of Internal Medicine, 2009, 169, 1500.	3.8	193
57	Refining Patient Selection for Primary Prevention Implantable Cardioverter-Defibrillator Therapy. Circulation, 2009, 120, 825-827.	1.6	12

#	ARTICLE	IF	CITATIONS
58	Outcomes of Early Risk Stratification and Targeted Implantable Cardioverter-Defibrillator Implantation After ST-Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. <i>Circulation</i> , 2009, 120, 194-200.	1.6	68
59	Metaiodobenzylguanidine (mIBG) molecular imaging in implantable cardioverter defibrillator (ICD) therapy planning: a health technology assessment issue. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2009, 36, 1346-1350.	6.4	2
60	Primary prevention with the ICD in clinical practice: not as straightforward as the guidelines suggest?. <i>Netherlands Heart Journal</i> , 2009, 17, 107-110.	0.8	9
61	The ABCD (Alternans Before Cardioverter Defibrillator) Trial. <i>Journal of the American College of Cardiology</i> , 2009, 53, 471-479.	2.8	223
62	Indications for Implantable Cardioverter-Defibrillators Based on Evidence and Judgment. <i>Journal of the American College of Cardiology</i> , 2009, 54, 747-763.	2.8	88
63	Examination of the Effect of Implantable Cardioverter-Defibrillators on Health-Related Quality of Life. <i>American Journal of Cardiovascular Drugs</i> , 2009, 9, 393-400.	2.2	38
64	Implantable Cardioverter-Defibrillator Therapy for Primary Prevention of Sudden Cardiac Death: An Argument for Restraint. <i>Cardiac Electrophysiology Clinics</i> , 2009, 1, 105-116.	1.7	3
65	Predictors of long-term mortality in Multicenter Automatic Defibrillator Implantation Trial II (MADIT) II. <i>Journal of the American College of Cardiology</i> , 2009, 53, 1471-1479.	0.7	66
66	Implantable Cardioverter Defibrillator in Patients with Coronary Artery Disease. <i>Cardiac Electrophysiology Clinics</i> , 2009, 1, 79-93.	1.7	0
67	El desfibrilador automático implantable. Evitando la muerte súbita. <i>Revista Española De Cardiología Suplementos</i> , 2010, 10, 32A-39A.	0.2	2
68	Cost-Effectiveness of Implantable Cardioverter-Defibrillators in Brazil: Primary Prevention Analysis in the Public Sector. <i>Value in Health</i> , 2010, 13, 160-168.	0.3	19
69	Implantation Trends and Patient Profiles for Pacemakers and Implantable Cardioverter Defibrillators in the United States: 1993-2006. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010, 33, 705-711.	1.2	188
70	Predictors of Early Mortality in Patients Age 80 and Older Receiving Implantable Defibrillators. <i>PACE - Pacing and Clinical Electrophysiology</i> , 2010, 33, 981-7.	1.2	20
71	Custo-efetividade de cardiodesfibriladores implantáveis no Brasil nos setores público e privado. <i>Arquivos Brasileiros De Cardiologia</i> , 2010, 95, 577-586.	0.8	20
72	Long-Term Outcome After ICD and CRT Implantation and Influence of Remote Device Follow-Up. <i>Circulation</i> , 2010, 122, 2359-2367.	1.6	466
73	Long-Term Benefit of Primary Prevention With an Implantable Cardioverter-Defibrillator. <i>Circulation</i> , 2010, 122, 1265-1271.	1.6	205
74	ACCF/AHA New Insights Into the Methodology of Performance Measurement. <i>Circulation</i> , 2010, 122, 2091-2106.	1.6	73
75	Proportion of patients needing an implantable cardioverter defibrillator on the basis of current guidelines: impact on healthcare resources in Italy and the USA. Data from the ALPHA study registry. <i>Europace</i> , 2010, 12, 1105-1111.	1.7	14

#	ARTICLE	IF	CITATIONS
76	Relationship between cardiac autonomic function and sustained ventricular tachyarrhythmias in patients with an implantable cardioverter defibrillators. <i>Europace</i> , 2010, 12, 1725-1731.	1.7	23
77	Is there new hope for sudden cardiac death prevention early after myocardial infarction?. <i>Heart Rhythm</i> , 2010, 7, 1598-1599.	0.7	3
78	ACCF/AHA New Insights Into the Methodology of Performance Measurement. <i>Journal of the American College of Cardiology</i> , 2010, 56, 1767-1782.	2.8	58
79	Patient Expectations From Implantable Defibrillators to Prevent Death in Heart Failure. <i>Journal of Cardiac Failure</i> , 2010, 16, 106-113.	1.7	110
80	Cost-effectiveness of implantable cardioverter defibrillators in patients ≥65 years of age. <i>American Heart Journal</i> , 2010, 160, 122-131.	2.7	35
81	Chronic Cardiac Failure. , 2010, , 272-285.		1
82	Implications of ICU triage decisions on patient mortality: a cost-effectiveness analysis. <i>Critical Care</i> , 2011, 15, R56.	5.8	71
83	Cost-effectiveness of Implantable Cardioverter-Defibrillators and Cardiac Resynchronization Therapy. <i>Cardiac Electrophysiology Clinics</i> , 2011, 3, 421-440.	1.7	0
84	Economic Implications and Cost-effectiveness of Implantable Cardioverter Defibrillator and Cardiac Resynchronization Therapy. <i>Heart Failure Clinics</i> , 2011, 7, 241-250.	2.1	5
85	Myocardial Fibrosis Predicts Appropriate Device Therapy in Patients With Implantable Cardioverter-Defibrillators for Primary Prevention of Sudden Cardiac Death. <i>Journal of the American College of Cardiology</i> , 2011, 57, 821-828.	2.8	279
86	Cost-Effectiveness of Implantable Defibrillators after Myocardial Infarction Based on 8-Year Follow-Up Data (MADIT II). <i>Value in Health</i> , 2011, 14, 812-817.	0.3	18
87	Editorial: Sudden Death in Heart Failure: An Ounce of Prediction is Worth a Pound of Prevention. <i>Heart Failure Clinics</i> , 2011, 7, xiii-xviii.	2.1	4
88	Author Reply“ICD Implantation Early After Acute ST Elevation Myocardial Infarction. <i>Heart Rhythm</i> , 2011, 8, e2.	0.7	0
89	Management of Arrhythmias in Heart Failure. , 2011, , 765-786.		1
90	Analysis of Willingness to Pay for Implantable Cardioverter“Defibrillator Therapy. <i>American Journal of Cardiology</i> , 2011, 107, 423-427.	1.6	6
91	Health care utilisation after defibrillator implantation for primary prevention according to the guidelines in 2 Dutch academic medical centres. <i>Netherlands Heart Journal</i> , 2011, 19, 405-411.	0.8	6
92	Prediction of sudden cardiac death: next steps in pursuit of effective methodology. <i>Journal of Interventional Cardiac Electrophysiology</i> , 2011, 31, 101-107.	1.3	20
93	Timing of defibrillator implant after acute myocardial infarction: what's new?. <i>Europace</i> , 2011, 13, 455-457.	1.7	0

#	ARTICLE	IF	CITATIONS
94	Infrequent physician use of implantable cardioverter-defibrillators risks patient safety. Heart, 2011, 97, 1655-1660.	2.9	17
95	Risk Stratification for Arrhythmic Sudden Cardiac Death. Circulation, 2011, 123, 2423-2430.	1.6	155
96	Mortality and Cost Associated With Cardiovascular Implantable Electronic Device Infections. Archives of Internal Medicine, 2011, 171, 1821.	3.8	292
97	Applying health economics for policy decision making: do devices differ from drugs?. Europace, 2011, 13, ii54-ii58.	1.7	40
98	Chronic Heart Failure: We Are Fighting the Battle, but Are We Winning the War?. Scientifica, 2012, 2012, 1-16.	1.7	7
99	Psychological vulnerability, ventricular tachyarrhythmias and mortality in implantable cardioverter defibrillator patients: is there a link?. Expert Review of Medical Devices, 2012, 9, 377-388.	2.8	27
100	Sudden cardiac death and implantable cardioverter defibrillators: two modern epidemics?. Europace, 2012, 14, 787-794.	1.7	22
101	Cost-Effectiveness of Transcatheter Aortic Valve Replacement. Circulation, 2012, 125, 1076-1077.	1.6	13
102	Real-World Data on the Lifespan of Implantable Cardioverter-Defibrillators Depending on Manufacturers and the Amount of Ventricular Pacing. Journal of Cardiovascular Electrophysiology, 2012, 23, 1336-1342.	1.7	60
103	Electrocardiographic left ventricular hypertrophy predicts arrhythmia and mortality in patients with ischemic cardiomyopathy. Journal of Interventional Cardiac Electrophysiology, 2012, 34, 237-245.	1.3	12
104	Applicability of a Risk Score for Prediction of the Long-Term (8-Year) Benefit of the Implantable Cardioverter-Defibrillator. Journal of the American College of Cardiology, 2012, 59, 2075-2079.	2.8	137
105	Prediction of Mortality in Clinical Practice for Medicare Patients Undergoing Defibrillator Implantation for Primary Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2012, 60, 1647-1655.	2.8	162
106	ICDs, Guidelines, and National Registries: Opportunities to Enhance Quality of Patient Care. PACE - Pacing and Clinical Electrophysiology, 2012, 35, 253-258.	1.2	1
107	Nonparametric Inference for Median Costs with Censored Data. Biometrics, 2012, 68, 717-725.	1.4	14
108	Missing data in trial-based cost-effectiveness analysis: the current state of play. Health Economics (United Kingdom), 2012, 21, 187-200.	1.7	70
109	Trends in the use of implantable cardioverter defibrillators in Australia: a 10-year nationwide study from 2000-2009. Internal Medicine Journal, 2013, 43, 888-895.	0.8	6
110	Implementation of guidelines for implantable cardioverter-defibrillator therapy in clinical practice: Which patients do benefit?. Netherlands Heart Journal, 2013, 21, 274-283.	0.8	29
111	Multi-contrast late enhancement CMR determined gray zone and papillary muscle involvement predict appropriate ICD therapy in patients with ischemic heart disease. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 57.	3.3	21

#	ARTICLE	IF	CITATIONS
112	Quantification of Survival Gain From Cardiac Resynchronization Therapy. Journal of the American College of Cardiology, 2013, 62, 2406-2413.	2.8	18
113	Absolute risk reduction in total mortality with implantable cardioverter defibrillators: analysis of primary and secondary prevention trial data to aid risk/benefit analysis. Europace, 2013, 15, 813-819.	1.7	37
114	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Journal of the American College of Cardiology, 2013, 61, e6-e75.	2.8	736
115	Cost-Effectiveness of Cardiac Resynchronization Therapy in the MADIT-CRT Trial. Journal of Cardiovascular Electrophysiology, 2013, 24, 66-74.	1.7	50
116	Polymorphic Ventricular Tachycardia-Part II: The Channelopathies. Current Problems in Cardiology, 2013, 38, 503-548.	2.4	5
117	Causes and prevention of sudden cardiac death in the elderly. Nature Reviews Cardiology, 2013, 10, 135-142.	13.7	39
118	2012 ACCF/AHA/HRS Focused Update Incorporated Into the ACCF/AHA/HRS 2008 Guidelines for Device-Based Therapy of Cardiac Rhythm Abnormalities. Circulation, 2013, 127, e283-352.	1.6	803
119	Estimating incremental cost-effectiveness ratios and their confidence intervals with different terminating events for survival time and costs. Biostatistics, 2013, 14, 422-432.	1.5	2
120	Arrhythmogenic Right Ventricular Cardiomyopathy (ARVC/D): A Systematic Literature Review. Clinical Medicine Insights: Cardiology, 2013, 7, CMC.S10940.	1.8	85
121	ECG Quantification of Myocardial Scar and Risk Stratification in MADIT-II. Annals of Noninvasive Electrocardiology, 2013, 18, 427-435.	1.1	15
122	The cost-effectiveness of primary prophylactic implantable defibrillator therapy in patients with ischaemic or non-ischaemic heart disease: a European analysis. European Heart Journal, 2013, 34, 211-219.	2.2	60
123	Generalized Redistribute-to-the-Right Algorithm: Application to the Analysis of Censored Cost Data. Journal of Statistical Theory and Practice, 2013, 7, 304-323.	0.5	3
124	The Healthcare Utilization and Cost of Treating Patients Experiencing Inappropriate Implantable Cardioverter Defibrillator Shocks: A Propensity Score Study. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 1315-1323.	1.2	16
125	Cost-Effectiveness of Primary Prevention Implantable Cardioverter Defibrillator Treatment: Data from a Large Clinical Registry. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 25-34.	1.2	12
126	Cardiac Implantable Electronic Device Reutilization: Battery Life of Explanted Devices at a Tertiary Care Center. PACE - Pacing and Clinical Electrophysiology, 2014, 37, 569-575.	1.2	14
127	Cost-Effectiveness Analysis: A Proposal of New Reporting Standards in Statistical Analysis. Journal of Biopharmaceutical Statistics, 2014, 24, 443-460.	0.8	27
128	Evaluation of the need of elective implantable cardioverter-defibrillator generator replacement in primary prevention patients without prior appropriate ICD therapy. Heart, 2014, 100, 1188-1192.	2.9	31
129	The Cost Effectiveness of Implantable Cardioverter Defibrillators: A Systematic Review of Economic Evaluations. Applied Health Economics and Health Policy, 2014, 12, 41-49.	2.1	13



#	ARTICLE	IF	CITATIONS
130	Nonparametric inference for timeâ€dependent incremental costâ€effectiveness ratios. <i>Statistics in Medicine</i> , 2015, 34, 4057-4069.	1.6	0
131	Implantable cardioverter-defibrillators in the elderly: rationale and specific age-related considerations. <i>Europace</i> , 2015, 17, 174-186.	1.7	64
132	Economic evaluations of implantable cardioverter defibrillators: a systematic review. <i>European Journal of Health Economics</i> , 2015, 16, 879-893.	2.8	11
133	An Electrophysiologist Perspective on Risk Stratification in Heart Failure: Can Better Understanding of the Condition of the Cardiac Sympathetic Nervous System Help?. <i>Journal of Nuclear Medicine</i> , 2015, 56, 59S-64S.	5.0	4
134	The effect of duration of follow-up and presence of competing risk on lifespan-gain from implantable cardioverter defibrillator therapy: who benefits the most?. <i>European Heart Journal</i> , 2015, 36, 1676-1688.	2.2	31
135	Median-based incremental cost-effectiveness ratios with censored data. <i>Journal of Biopharmaceutical Statistics</i> , 2016, 26, 552-564.	0.8	6
136	Nonparametric inference for the joint distribution of recurrent marked variables and recurrent survival time. <i>Lifetime Data Analysis</i> , 2017, 23, 207-222.	0.9	0
137	Implantable cardioverter/defibrillators for primary prevention in dilated cardiomyopathy post-DANISH: an updated meta-analysis and systematic review of randomized controlled trials. <i>Clinical Research in Cardiology</i> , 2017, 106, 501-513.	3.3	38
138	Assessing physician knowledge regarding indications for a primary prevention implantable defibrillator and potential barriers for referral. <i>Journal of Cardiovascular Electrophysiology</i> , 2017, 28, 1334-1341.	1.7	5
139	Dutch outcome in implantable cardioverter-defibrillator therapy (DO-IT): registry design and baseline characteristics of aâ€prospective observational cohort study to predict appropriate indication for implantable cardioverter-defibrillator. <i>Netherlands Heart Journal</i> , 2017, 25, 574-580.	0.8	12
140	Handling Missing Data in Within-Trial Cost-Effectiveness Analysis: A Review with Future Recommendations. <i>PharmacoEconomics - Open</i> , 2017, 1, 79-97.	1.8	40
141	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death: Executive summary. <i>Heart Rhythm</i> , 2018, 15, e190-e252.	0.7	448
142	2017 AHA/ACC/HRS guideline for management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. <i>Heart Rhythm</i> , 2018, 15, e73-e189.	0.7	262
143	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. <i>Journal of the American College of Cardiology</i> , 2018, 72, 1677-1749.	2.8	382
144	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death: Executive Summary. <i>Circulation</i> , 2018, 138, e210-e271.	1.6	250
145	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. <i>Circulation</i> , 2018, 138, e272-e391.	1.6	468
146	Relationship between left ventricular dyssynchrony and scar burden in the genesis of ventricular tachyarrhythmia. <i>Journal of Nuclear Cardiology</i> , 2018, 25, 555-569.	2.1	18
147	Evaluation of Need for Implantable Cardioverter-Defibrillator by Thallium-201 Scintigraphy Among Japanese Patients With Prior Myocardial Infarction. <i>Circulation Journal</i> , 2018, 83, 56-66.	1.6	0

#	ARTICLE	IF	CITATIONS
148	Developing a risk score to predict mortality in the first year after implantable cardioverter defibrillator implantation: Data from the Israeli ICD Registry. Journal of Cardiovascular Electrophysiology, 2018, 29, 1540-1547.	1.7	6
149	2017 AHA/ACC/HRS Guideline for Management of Patients With Ventricular Arrhythmias and the Prevention of Sudden Cardiac Death. Journal of the American College of Cardiology, 2018, 72, e91-e220.	2.8	991
150	Consideration for primary prevention implantable cardioverter defibrillators differ between specialities. Postgraduate Medical Journal, 2019, 95, 205-209.	1.8	1
151	Prophylactic implantable cardioverter-defibrillator in the very elderly. Europace, 2019, 21, 1063-1069.	1.7	11
152	Non-ischemic cardiomyopathy in the elderly: A shocking conundrum. Indian Pacing and Electrophysiology Journal, 2019, 19, 1-3.	0.6	0
153	Influence function-based empirical likelihood for inference of quantile medical costs with censored data. Statistical Methods in Medical Research, 2020, 29, 1913-1934.	1.5	1
154	Decision-making regarding primary prevention implantable cardioverter-defibrillators among older adults. Clinical Cardiology, 2020, 43, 187-195.	1.8	10
156	Primary Prevention ICDs in Nonischemic Cardiomyopathy. Journal of the American College of Cardiology, 2020, 76, 416-418.	2.8	4
157	Cardiac Imaging With 123I-meta-iodobenzylguanidine and Analogous PET Tracers: Current Status and Future Perspectives. Seminars in Nuclear Medicine, 2020, 50, 331-348.	4.6	11
158	Practice Guidelines for the Diagnosis and Management of Systolic Heart Failure in Low- and Middle-Income Countries. Global Heart, 2013, 8, 141.	2.3	4
159	Deterrence effects of antifraud and abuse enforcement in health care. Journal of Health Economics, 2021, 75, 102405.	2.7	7
160	PET and SPECT in the Evaluation of Cardiac Implantable Electronic Devices. , 2021, , 619-674.		0
161	Preventive implantable cardioverter defibrillator therapy in contemporary clinical practice: need for more stringent selection criteria. ESC Heart Failure, 2021, 8, 3656-3662.	3.1	4
162	Same-day discharge after implantation of cardiac implantable electronic devices: A systematic review and meta-analysis. PACE - Pacing and Clinical Electrophysiology, 2021, 44, 1925-1933.	1.2	9
163	Empirical likelihood-based confidence intervals for mean medical cost with censored data. Statistics in Medicine, 2017, 36, 4061-4070.	1.6	1
165	Patient barriers to implantable cardioverter defibrillator implantation for the primary prevention of sudden cardiac death in patients with heart failure and reduced ejection fraction. Singapore Medical Journal, 2016, 57, 182-187.	0.6	14
166	Use and Abuse of Internal Cardioverter Defibrillators for Primary Prevention. Arrhythmia and Electrophysiology Review, 2012, 1, 46.	2.4	4
167	Implantable cardioverter defibrillators for the treatment of arrhythmias and cardiac resynchronisation therapy for the treatment of heart failure: systematic review and economic evaluation. Health Technology Assessment, 2014, 18, 1-560.	2.8	58

#	ARTICLE	IF	CITATIONS
168	Cost effectiveness of coronary revascularisation. EuroIntervention, 2010, 5, 763-767.	3.2	6
169	Indications for Implantable Cardioverter Defibrillators. , 2008, , 495-546.		0
170	38 De implanteerbare cardioverter-defibrillator. , 2008, , 331-340.		0
171	Cardioversor-desfibrilador na preven��o prim��ria de morte s��bita: para todos ou para poucos?. Arquivos Brasileiros De Cardiologia, 2008, 91, 63-4.	0.8	1
172	Implantable Cardioverter Defibrillator Therapy: A Single Center Experience in Saudi Arabia. Open Cardiovascular Medicine Journal, 2010, 4, 192-197.	0.3	2
173	Implantable cardioverter defibrillators in patients with coronary artery disease. , 2011, , 417-427.		0
174	Clinical Trials of Defibrillator Therapy. , 2011, , 257-278.		0
175	Clinical Role of Antiarrhythmic Drugs in the Prevention of Sudden Death. , 2013, , 501-524.		0
176	Novel Predictors of Sudden Cardiac Death. , 2013, , 301-314.		0
177	Application of microvolt T-wave alternans testing in scheduling implantable cardioverter-defibrillator placement for the primary prevention of sudden cardiac death in patients with left ventricular dysfunction. Kardiologia Polska, 2015, 73, 429-436.	0.6	2
179	Dyssynchrony. , 2022, , 83-102.		0
180	Cost-Effectiveness of ICD Therapy in the Prevention of Sudden Death in CAD and/or HF Patients. , 2007, , 263-275.		0
181	Clinical Role of Antiarrhythmic Drugs in the Prevention of Sudden Death. , 2008, , 733-759.		0
182	Current developments in microvolt T-wave alternans. Indian Pacing and Electrophysiology Journal, 2006, 6, 214-25.	0.6	1
183	Comparative effectiveness research: a cornerstone of healthcare reform?. Transactions of the American Clinical and Climatological Association, 2010, 121, 141-54; discussion 154-5.	0.5	6
184	Physicians' knowledge and attitudes regarding implantable cardioverter-defibrillators. Cardiology Journal, 2010, 17, 267-73.	1.2	21
185	ICD Implantation Practice Within Europe: How To Explain The Differences Beyond Economy?. Journal of Atrial Fibrillation, 2015, 8, 1262.	0.5	1
186	2022 ACC/AHA/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of Cardiac Failure, 2022, 28, 810-830.	1.7	42

#	ARTICLE	IF	CITATIONS
187	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 1757-1780.	2.8	314
188	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR00000000000001063.	1.6	756
189	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, 101161CIR00000000000001062.	1.6	133
190	2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure. Journal of the American College of Cardiology, 2022, 79, e263-e421.	2.8	774
191	Implantable Cardioverter-Defibrillator Therapy. , 0, , 18-28.		0
193	Net benefit regression with censored cost-effectiveness data from randomized or observational studies. Statistics in Medicine, 2022, 41, 3958-3974.	1.6	1
194	Economic evaluation in cardiac electrophysiology: Determining the value of emerging technologies. Frontiers in Cardiovascular Medicine, 0, 10, .	2.4	0
195	Metabolomics Profiling Predicts Ventricular Arrhythmia in Patients with an Implantable Cardioverter Defibrillator. Journal of Cardiovascular Translational Research, 2024, 17, 91-101.	2.4	2
197	The economics of heart failure care. Progress in Cardiovascular Diseases, 2024, 82, 90-101.	3.1	0